VRTX
Vertex Pharmaceuticals Inc.
$470.90
▼ -1.30%
−$6.20
NASDAQ · Healthcare · Biotechnology
· price updated 9h ago
Vertex Pharmaceuticals Inc.
VRTX · NASDAQ · Healthcare · Biotechnology · price updated 9h ago
$470.90
▼ -1.30% · −$6.20 today
AI research · $470.90
VRTX, researched
Crinetics overhang fades, growth story intact
refreshed Jul 15
price position
Where VRTX sits now
52-week range
Low$362.50
High$533.67
Today $470.90
RSI (14)
20.9Oversold
03070100
fundamentals
Business quality and valuation
Operating record
What the business has actually produced
Revenue
Capital structure
Cash versus debt
Cash & investments$7.2B
Total debt$2.0B
Net cash after debt$5.3B
Valuation
What the market charges
Forward P/E
Price against expected earnings
Needs attention · 27% above Sector avg
25.08x
Price / sales
Value assigned to each sales dollar
Rich · Above 8x annual sales
9.91x
Price / FCF
Price against free cash generation
Reasonable · Between 20x and 35x free cash flow
32.64x
EV / EBITDA
Operating value including debt
Rich · Above 22x EBITDA
22.47x
Quality
How efficiently it compounds
ROIC
Return earned on invested capital
Strong · At least 15% return on capital
28.6%
ROE
Profit generated from shareholder equity
Favorable · Exceptional vs sector peers
24.2%
Debt / equity
Balance-sheet leverage
Favorable · Exceptional vs sector peers
0.10x
Current ratio
Short-term assets against liabilities
Strong · Comfortable short-term liquidity
3.02x
Business mix
Mar 31, 2026Trikafta and Kaftrio100.0% · $10.1B
Geographic mix
Mar 31, 2026United States62.8% · $7.7B
Europe29.3% · $3.6B
Other8.0% · $973.3M
Selected financial data sourced from StockAnalysis and refreshed weekly. Figures may be delayed and are for research context, not investment advice.
peer comparison
How VRTX compares
| company | mkt cap | P/E | rev growth | score |
|---|---|---|---|---|
| $121.09B | 28.3 | +10.1% | 72 |
 | $10.69B | 18.4 | +23.5% | 78 |
 | $4.88B | 20.3 | +10.3% | 77 |
 | $31.49B | 32.9 | +15.5% | 77 |
 | $1.08T | 41.4 | +47.4% | 76 |
activity
What is moving VRTX
US stock research
About Vertex Pharmaceuticals Inc. (VRTX) stock
Vertex Pharmaceuticals Inc. tracked in the US core universe. VRTX was -1.3% in the latest available session at $470.90. Its reported market value was $121.09B with a trailing P/E of 28.3. Latest reported revenue was $12.22B, changing +10.1% year over year, with $4.34B in net income.
Market snapshot updated Aug 3, 2026, 7:59 PM UTC.
- Latest available price
- $470.90
- Day change
- -1.3%
- Market cap
- $121.09B
- P/E (TTM)
- 28.3
- Revenue growth
- +10.1%
- Industry
- Biotechnology